Cargando…
Did COVID-19 Push CAR-T to the Outpatient Setting?
Autores principales: | Harris, Alyssa, Dolan, Carina, Hohmann, Samuel, Shippey, Ernie, Epting, Gladys |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930044/ http://dx.doi.org/10.1016/S2666-6367(22)00424-9 |
Ejemplares similares
-
Delay in COVID-19 Presentation in Patients Recently Treated with CD-19 Directed CAR-T Therapy
por: Wuliji, Natalie, et al.
Publicado: (2022) -
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022) -
Comparison of Humoral and T-Cell Response after Sars-Cov-2 Vaccination Among Patients before and after Chimeric Antigen Receptor-Modified T Cell (CAR-T cell) Therapy
por: Gonzalez, Michael A, et al.
Publicado: (2022) -
How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023) -
How I treat refractory CRS and ICANS after CAR T-cell therapy
por: Jain, Michael D., et al.
Publicado: (2023)